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Abstract
Purpose Cervical cancer metastasis results in poor prognosis and increased mortality, which is not separated from inflamma-
tory reactions accumulated by prostaglandin E2 (PGE2). As a specific G-protein coupled PGE2 receptor, EP3 is demonstrated 
as a negative prognosticator of cervical malignancy. Now, we aimed to investigate the pathological mechanism of EP3 in 
modulating cervical cancer carcinogenesis.
Methods Bioinformatics analysis was used to identify PAI-1 and uPAR correlations with EP3 expression, as well as the 
prognosis of cervical cancer patients. In vitro analyses were carried out to investigate the role of EP3 on cervical cancer 
proliferation and migration.
Results In vitro studies showed that sulprostone (an EP3 agonist) enhanced the proliferation and migration of cervical can-
cer cells, whereas silencing of EP3 inhibited their proliferation and migration. Furthermore, EP3 knockdown increased the 
expression of plasminogen activator inhibitor type 1 (PAI-1), urokinase-type plasminogen activator receptor (uPAR), and 
phosphorylated extracellular signal-regulated kinases 1/2 (p-ERK1/2), but decreased p53 expression. Bioinformatics analysis 
showed that both PAI-1 and uPAR were correlated with EP3 expression, as well as the prognosis of cervical cancer patients. 
The survival analysis further showed that uPAR overexpression (IRS≥2) was correlated with a lower overall survival rate 
of cervical cancer patients with advanced stages (FIGO III-IV).
Conclusion These results indicated that EP3 signaling pathway might facilitate the migration of cervical cancer cells through 
modulating uPAR expression. Therefore, EP3 and uPAR could represent novel therapeutic targets in the treatment of cervi-
cal cancer in advantaged stages.
Keywords Cervical cancer · Prostaglandin  E2 receptor 3 (EP3) · Urokinase-type plasminogen activator receptor (uPAR) · 
Plasminogen activator inhibitor type 1 (PAI-1)
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DFS  Disease-free survival
PGE2  Prostaglandin  E2
EP3  Prostaglandin  E2 receptor 3
uPAR  Urokinase-type plasminogen activator 
receptor
PAI-1  Plasminogen activator inhibitor type 1
ECM  Extracellular matrix
ERK1/2  Extracellular signal-regulated kinases 1/2
p-ERK1/2  Phosphorylated Extracellular signal-regulated 
Kinases 1/2
TGF-β1  Transforming Growth Factor-β1
Introduction
Cervical cancer is the fourth most common cancer in women 
worldwide and approximately 510,000 new cases of women 
will be diagnosed in 2030 as today (Ginsburg et al. 2017). 
According to the cancer statistics of the United States in 
2019, there were an estimated 13,170 cases and 4250 deaths 
from cervical cancer (Siegel et al. 2019). Approximately half 
of the cervical cancer patients die from metastasizing tumors 
globally (Wright and Kuhn 2012). The two main malignant 
epithelial cervical cancer types are the squamous cell carci-
noma and the adenocarcinoma (Young and Clement 2002). 
The human papillomavirus (HPV) infection is the crucial 
risk factor for cervical cancer and is the primary cause of 
cervical cancer (Schiffman et al. 2011). Inflammation after 
HPV infection is a driving force that increases cervical 
cancer development (Deivendran et al. 2014). Cyclooxy-
genase-2 (COX-2) and prostaglandin  E2  (PGE2) are well-
known inflammatory factors and up-regulated synthesis of 
both has been identified in the cervical carcinoma (). As 
the rate-limiting enzyme of  PGE2 synthesis, COX-2 is not 
only related to poor overall survival (OS) and poor disease-
free survival (DFS) in cervical cancer patients, but also is 
associated with poor DFS in a chemo-radiation subgroup of 
cervical cancer patients (Huang et al. 2013).
The effects of  PGE2 are mainly facilitated by four spe-
cific membrane-bound G-protein-coupled EP receptors 
(EP1-EP4) with various signaling pathways (Sokolowska 
et al. 2015). It is suggested that  PGE2 regulates the func-
tion of cervical cancer cells mainly via cyclic adenosine 
monophosphate (cAMP) linked EP2/EP4 signaling pathway 
(). GW627368X (a highly selective EP4 antagonist) inhib-
its the proliferation and angiogenesis of cervical carcinoma 
by blocking EP4/epidermal growth factor receptor (EGFR) 
signaling pathway in cervical cancer cell lines (HeLa, SiHa 
and ME180) and suppresses the tumor size in xenograft mice 
model (Parida et al. 2016). Our latest publication demon-
strated that high expression of EP3 is associated with poor 
prognosis in overall survival rates of cervical cancer patients 
in both squamous cell carcinoma and adenocarcinoma 
(Heidegger et al. 2017). EP3 is a unique  PGE2 receptor, 
since the human EP3 gene consists of ten exons and nine 
introns, encoding at least eight distinct EP3 splice variants 
(Kotani et al. 1997). EP3 has been reported to mediate the 
carcinogenesis in numerous tumors with conflicting effects 
(Fujino et al. 2011; Hoshikawa et al. 2009; Kang et al. 2011; 
Kashiwagi et al. 2013; Ma et al. 2013; Shoji et al. 2004; 
Yamaki et al. 2004; Zhu et al. 2018). However, the molecular 
pathological mechanism of EP3 in cervical cancer develop-
ment is still unknown.
Plasminogen activator contributes to proteolytic degra-
dation and intercellular interaction damage during tumor 
metastasis. Plasminogen activator inhibitor type 1 (PAI-1) 
is the main inhibitor of the plasminogen activating system, 
which consists of urokinase-type plasminogen activator 
(uPA) and uPA receptor (uPAR) (Zorio et al. 2008).  PGE2 
combining with the EP1/EP3 receptor regulates the levels 
of PAI-1 in cardiac fibroblasts (Kassem et al. 2014). PAI-1 
inhibits the activation of uPA and plays a crucial role in 
cancer invasion and metastasis by remodelling the extra-
cellular matrix (ECM). PAI-1 enhances tumor cell prolif-
eration by encouraging S-phase entry (Giacoia et al. 2014) 
and increases migration by binding uPA/uPAR complex 
(Andreasen et al. 2000). PAI-1/uPA/uPAR/low-density lipo-
protein receptor-related protein (LRP)/integrin complexes 
are initiating an “adhesion–detachment–re-adhesion” cycle 
to promote tumor cell migration (Andreasen et al. 2000; 
Carter and Church 2009). Overexpressions of both PAI-1 
(Hazelbag et al. 2004; Horn et al. 2002) and uPA (Fujishiro 
et al. 1994; Sugimura et al. 1992) are associated with poor 
prognosis in cervical cancer patients. However, Sato et al. 
proposed that lower levels of PAI-1 are produced in cervical 
cancer cells that distant from the basal membrane, espe-
cially in cervical cancer stem cells (Sato et al. 2016). These 
conflicting reports indicate the complex roles of PAI-1 in 
cervical carcinoma development, which requires further 
investigations. The uPAR protein in the serum (Jing et al. 
2012) and uPAR mRNA in the specimen (Sasaki et al. 2014) 
are identified as new prognosticators of cervical cancers. 
uPAR can be cleaved into soluble uPAR, both full-length 
and cleaved uPAR are involved in cell signaling, prolifera-
tion, migration and invasion of tumor cells (Magnussen et al. 
2017). However, the correlation between uPAR and overall 
survival of cervical cancer has not been clarified.
In the present study, we aimed to explore the functional 
roles of EP3 in the tumor genesis of cervical cancer, espe-
cially in the migration. In in vitro studies, we observed that 
EP3 silencing attenuated the proliferation and migration 
of cervical cancer cells and upregulated the expression of 
PAI-1 and uPAR. This was in accordance with the find-
ing that EP3 was significantly correlated with PAI-1 and 
uPAR from publicly available databases. By immunohis-
tochemistry, we demonstrated that high uPAR expression 
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was associated with the poor prognosis of cervical cancer 
patients with advanced stages (FIGO III–IV). Our present 
study shed light on the critical role of EP3 and uPAR in 
regulating migration in cervical cancer in advantaged stages.
Materials and methods
Bioinformatics
The gene set enrichment analysis (GSEA) software was per-
formed to calculate the corresponding signaling pathways 
associated with EP3 (https ://www.softw are.broad insti tute.
org/gsea/index .jsp). The cut-off criteria for GSEA were nom-
inal P value < 0.05 and false discovery rate (FDR) < 0.25. 
TIMER database was applied to identify the correlation 
between EP3 and PAI-1 or uPAR (https ://cistr ome.shiny 
apps.io/timer /). Both of GSEA and TIMER databased are 
based on the cervical squamous cell carcinoma and endocer-
vical adenocarcinoma (CESC) in the Cancer Genome Atlas 
(TCGA) dataset (https ://www.cance r.gov). We analyzed the 
survival rate in groups with differently expressed PAI-1 and 
uPAR by screening out the relevant documents and clinical 
information related to CESC in GEPIA database (https ://
gepia .cance r-pku.cn/) and UALCAN database (https ://ualca 
n.path.uab.edu/index .html), respectively.
Cell lines and culture
HeLa (RRID:CVCL_0030), SiHa (RRID: CVCL_0032), 
C-33A (RRID: CVCL_1094) and CaSki (RRID: 
CVCL_1100) cells were obtained from the American Type 
Culture Collection (ATCC) and were cultured in RPMI-1640 
medium (Gibco, USA) supplemented with 10% fetal bovine 
serum (FBS, Gibco, USA) without antibiotics or antimy-
cotics. According to the American Type Culture Collection 
(ATCC), HeLa cells are categorized as cervical adenocarci-
noma, SiHa cells are squamous cell carcinoma, CaSki cells 
are categorized as epidermoid carcinoma and C-33A cells 
are categorized as cervical carcinoma. All experiments were 
performed with mycoplasma-free cells. To investigate the 
effect of EP3 knockdown, cells were cultured in 96-well 
plates for the cell proliferation assay, 24-well plates for the 
wound healing assay and the enzyme-linked immunosorbent 
assay (ELISA), and 6-well plates for real-time polymerase 
chain reaction (RT-PCR) and western blotting.
Real time‑PCR (Taq Man)
Total RNA was obtained from cultured cells using a Rneasy 
Mini Kit (Qiagen, Hilden, Germany) and converted to cDNA 
with an MMLV Reverse Transcriptase First-Strand cDNA 
synthesis kit (epicenter, Madison, USA) as instructed by the 
protocol. The total EP3 mRNA levels were subjected to RT-
PCR using two different primers (Applied Biosystems, EP3 
Primer I, Nr. Hs00168755_m1, exon boundary 1–2; EP3 
Primer II, Nr. Hs00988369_m1, exon boundary 4–5). 20 μl 
reaction mixture containing 1 μl  TaqMan® Gene Expres-
sion Assay 20 ×, 10 μl  TaqMan® Fast Universal PCR Master 
Mix 2 ×, 1 μl cDNA template and 8 μl RNase-free water 
were prepared per probe on an Optical Fast 96-well plate and 
covered by an optical adhesive film. PCR assays were run 
by utilizing Applied Biosystems 7500 Fast Real-time PCR 
system. The amplification conditions were 20 s at 95 °C; 40 
cycles of 95 °C for 3 s and of 60 °C for 30 s. β-actin (Nr. 
Hs99999903_m1) was used as an endogenous control and 
the comparative CT method was applied for calculation.
EP3 silencing
Cervical cancer cells (HeLa, SiHa and C-33A) were seeded 
in six-well plates in 2 ml of RPMI-1640 medium to achieve 
40–60% confluence after 24 h. 1.2 µl of EP3 siRNA or 
the negative control siRNA and 4  µl of Lipofectamine 
RNAiMAX (Invitrogen, California, USA) were first diluted 
in 200 µl Opti-MEM (Gibco, California, USA) medium 
separately. Then we combined and added the correspond-
ing complex into each well, mixed gently, and incubated at 
37 °C in 5%  CO2 for 48 h. The knockdown efficiency was 
assessed by RT-PCR.
Cell proliferation assay
HeLa, SiHa and C-33A cells were seeded into 96-well plates 
and siRNA-mediated EP3 knockdown was conducted with 
the siRNA-Lipofectamine RNAiMAX mixture on day two. 
Cell proliferation was analyzed with a 5-bromo-2′-deoxy-
uridine (BrdU) labeling and detection kit (Roche Diagnos-
tics GmbH, Mannheim, Germany) according to the manu-
facturer’s instructions. Cells were incubated with BrdU 
(20 µl/well) for 24 h, and then fixed with fixing solution 
for 30 min. After adding anti-BrdU-POD working solution 
(100 µl/well), BrdU incorporation into the cellular DNA was 
measured by an ELISA technique. The optical density (OD) 
was examined at 450 nm using Elx800 universal Microplate 
Reader. At least six replicates were performed with each 
cell line. 100 nM of  PGE2 and L-798,106 were incubated 
with HeLa, SiHa and C-33A cells and the dimethyl sulfoxide 
(DMSO, 0.5%) served as a vehicle control. The BrdU assay 
was performed as describe above.
Wound healing assay
HeLa and SiHa cells were cultured in 24-well plates, starved 
overnight and on day two siRNA-mediated EP3 knockdown 
was treated for 48 h. On day three, the central fields of 
2192 Journal of Cancer Research and Clinical Oncology (2020) 146:2189–2203
1 3
confluent monolayers were scratched with 200 µl pipette tips 
to make artificial wound gaps. Then each well was rinsed 
with phosphate-buffered saline (PBS) and was then added 
fresh RPMI1640 containing 1% FBS. Cell migration was 
monitored by photographing with an inverse phase contrast 
microscope (Leica Dmi1, Leica, Wetzlar, Germany) for 0 h 
and 24 h. Photos of cells migration area were analyzed with 
software Image J (https ://image j.nih.gov/ij/). Scratch area 
was measured at 0 h and 24 h by image J, and the cell migra-
tion area = scratch area at 0 h—scratch area at 24 h.
Western blotting
Cell lysates were extracted from cervical cancer cells with 
radioimmunoprecipitation assay buffer (RIPA, Sigma-
Aldrich, R0278-50ML). 20 µg of cell lysates for western 
blotting were first separated in 10% sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis and then transferred 
to a polyvinylidene fluoride membrane (Bio-Rad, USA). 
The membrane was blocked in 4% skim milk powder and 
then incubated with the primary antibodies for 16 h at room 
temperature. Different primary antibodies were used as fol-
lows: rabbit polyclonal anti-EP3 antibody (Abcam, ab94496, 
1:500), mouse polyclonal anti-ERK1/2 antibody (Abcam, 
ab224313, 1:200), rabbit polyclonal anti-p-ERK1/2 antibody 
(Abcam, ab47339, 1:500), mouse monoclonal anti-p53 anti-
body (Santa Cruz, OD-1, 1:500) and rabbit polyclonal anti-
uPAR antibody (Abcam, ab218106, 1:300). β-actin was used 
as a housekeeping gene and mouse monoclonal anti-β-actin 
antibody was diluted as 1:1000 (Sigma, A5441). Afterwards, 
the membrane was incubated with the goat-anti-rabbit/-
mouse secondary antibody conjugated with alkaline phos-
phatase (1:1000 dilution, Jackson Immuno Research, UK), 
and detected with 5-bromo-4-chloro-3′-indolylphosphate/
nitro-blue tetrazolium (BCIP/NBT)-chromogen substrate 
solution (Promega). Western blots were scanned and quanti-
fied using the GelScan V6.0 1D Analysis Software (SERVA, 
Electrophoresis GmbH, Heidelberg, Germany). The blots 
were repeated at least three times.
PAI‑1 ELISA
Both HeLa and SiHa cells were cultured in 24-well plates 
and EP3 knockdown was conducted utilizing the siRNA-
Lipofectamine RNAiMAX mixture on day two. After 48 h, 
the supernatants of both cell lines were harvested. The levels 
of PAI-1 in the supernatants were measured with a com-
mercially available enzyme-linked immunosorbent assay 
(ELISA) kit (R&D system, DSE100, Minneapolis, MN, 
USA). A standard curve of PAI-1 was obtained for each 
assay and results were converted into ng/ml.
Patient samples
We analyzed paraffin-embedded cervical cancer samples 
from 250 patients having undergone surgeries for cervical 
cancer in the Department of Obstetrics and Gynecology in 
the Ludwig Maximilians University of Munich, Germany 
between 1993 and 2002. This study was approved by the 
ethical committee of the Medical Faculty, Ludwig Maximil-
ian University of Munich (approval number: 259-16). The 
written informed consent was obtained from each patient 
and all methods were performed in accordance with the rel-
evant guidelines and regulations. Staging and grading were 
assessed by two gynecological pathologists according to the 
criteria of FIGO and WHO. Follow-up data were received 
from the Munich Cancer Registry (Munich Tumour Center, 
Munich, Germany). Samples and clinical information were 
anonymized and encoded for statistical workup. All clinical 
information was blinded from the authors during experi-
mental analysis.
Detailed clinic characteristics of these cervical cancer 
patients are summarized in supplementary Table 1, which 
includes age, follow-up months, stages, grading, histology 
and survival months. The outcome was assessed by patients’ 
overall survival (OS). OS is defined as the time from diag-
nosis to the death or to the date of the last follow-up. 76% 
(190/250) of the cohort survived over 235 months and 19.6% 
(49/250) of the cohort died. The information of the rest 4.4% 
(11/250) of the cervical cancer patients is missing.
Table 1  Effects of EP3 
knockdown in HeLa, Siha and 
C-33A cervical cancer cell lines
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Immunohistochemistry
Paraffin-embedded slides (3 µm-thick) were dewaxed in 
xylol and washed in 100% ethanol, and then were incubated 
in methanol with 3%  H2O2 and rehydrated in a descending 
alcohol series. Slides were heated in a pressure cooker using 
sodium citrate buffer (pH = 6.0), containing 0.1 M citric acid 
and 0.1 M sodium citrate in distilled water. After cooling 
and washing in PBS, all slides were incubated with a block-
ing solution [Reagent 1, Zytochem-Plus HRP-Polymer-Kit 
(mouse/rabbit)] for 30 min to avoid non-specific binding 
of the primary antibodies. The slides were incubated with 
rabbit polyclonal anti-uPAR antibody (Abcam, ab218106, 
1:300 dilution) for 16 h at 4 °C. After washing, the second-
ary antibodies/complexes of HRP-polymer (Zytochem-Plus 
HRP Polymer-kit, Zytomed, Berlin, Germany) were applied. 
uPAR immunostaining was visualized with the substrate 
and the chromogen-3, 3′-diaminobenzidine (DAB; Dako, 
Hamburg, Germany) after 3 min. All slides were analyzed 
under the microscope by two independent observers using 
a Leitz (Wetzlar, Germany) photomicroscope. For the light 
microscopy analysis, a semi-quantitative IRS score was cal-
culated via the multiplication of optical staining intensity 
and the percentage range of positive stained cells (Remmele 
and Stegner 1987).
Metastatic colon carcinoma was used as a positive and 
negative control for the immunohistochemical staining of 
uPAR. Positive cells showed a brownish color and the nega-
tive control, as well as unstained cells, appeared blue (Worbs 
et al. 2007).
Statistical analysis
All data were analyzed with SPSS Statistics 24 software 
(IBM Corporation, Armonk, NY, USA) and are expressed 
as the mean ± standard deviation (SD). Mann–Whitney U 
test was applied for evaluating the proliferation rate and cell 
migration area. Wilcoxon test was performed for the evalu-
ation of PAI-1 expression levels and the band intensities 
of p-ERK1/2, ERK1/2, p53 and uPAR. Spearman’s rank 
correlation analysis was adopted to evaluate the correlation 
between two monotonic, nonlinear variables. The ROC curve 
Fig. 1  EP3 is associated with KEGG signaling pathways of cancer 
(a), calcium signaling (b), transforming growth factor-β (TGF-β) (c), 
ECM receptor interaction (d), adheren junction (e) and cell adhe-
sion molecules (CAMs) (f) in carcinogenesis. KEGG pathway gene 
sets in EP3 high versus low samples were obtained from The Cancer 
Genome Atlas (TCGA) dataset with the gene set enrichment analy-
sis (GSEA) software (https ://www.softw are.broad insti tute.org/gsea/
index .jsp). Normalized enrichment score (NES), nominal P value and 
false discovery rate (FDR) are shown in each plot. The cut-off crite-
ria for GSEA were nominal P value < 0.05 and false discovery rate 
(FDR) < 0.25
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was drawn to identify an appropriate cut-off value which can 
maximize the sum of sensitivity and specificity. Survival 
time was compared using Kaplan–Meier (long-rank) test 
method. We also applied a Cox-regression model for multi-
variate analyses. P-values < 0.05 were regarded as statisti-
cally significant.
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Results
Associated EP3 signaling pathways were 
upregulated in cancer
Our latest publication observed that enhanced expression 
of EP3 (IRS ≥ 2) is correlated with a poor prognosis in the 
OS of 250 cervical cancer patients after a 20-year follow-up 
analysis (Heidegger et al. 2017). Additionally, increased EP3 
expression is associated with higher tumor status, higher 
the International Federation of Gynecology and Obstetrics 
(FIGO)-classification, as well as with poorer survival (Hei-
degger et al. 2017). Based on this publication, we aimed 
to investigate the pathological mechanism of EP3 in the 
carcinogenesis of cervical cancer. First, we analyzed the 
relationship between EP3 expression and KEGG pathway 
gene sets with GSEA software (https ://www.softw are.broad 
insti tute.org/gsea/index .jsp). Pathways in cancer, calcium 
signaling and transforming growth factor-β (TGF-β) signal-
ing were significantly enriched (Fig. 1a–c), so were ECM 
receptor interaction, adheren junction and cell adhesion mol-
ecules (CAMs) signalings (Fig. 1d–f). This indicated that 
EP3 might be involved in the carcinogenesis, especially in 
tumor adhesion, migration and metastasis.
Knockdown of EP3 inhibits the proliferation 
and migration of HeLa and SiHa cells
Next, we investigated the effect of EP3 knockdown on the 
proliferation and migration of cervical cancer cells with 
in vitro cell culture. The EP3 expression levels in HeLa, 
SiHa, C-33A and CaSki cervical cancer cell lines were 
determined by western blotting and real-time polymerase 
chain reaction (RT-PCR) analyses. The protein expression of 
EP3 was higher in HeLa, SiHa and C-33A cells than CaSki 
cells detected by western blots (Fig. 2a). With the EP3 
primer I, the expression of EP3 in the mRNA level (Fig. 2b) 
showed the similar result as western blots. With the EP3 
primer II, the mRNA expression of EP3 was detected only 
in HeLa, SiHa and C-33A cells, and was not as high as with 
the EP3 primer I (Fig. 2b). Therefore, we used HeLa, SiHa 
and C-33A as cervical cancer models and the EP3 primer 
I for RT-PCR detection after the depletion of EP3 mRNA 
with siRNA. The EP3 mRNA level was downregulated by 
80% in HeLa cells, 62% in SiHa cells and 64% in C-33A 
cells compared to the negative control, respectively (each 
P < 0.05, Fig. 2c).
EP3 knockdown decreased the proliferation rate by 20.3% 
in HeLa cells (P = 0.028, Fig. 2D) and by 30.5% in SiHa 
cells (P = 0.036, Fig. 2d) compared to the relative negative 
control group after 48 h’ incubation. Since sulprostone (an 
EP1/EP3 agonist) can enhance the proliferation of HeLa 
cells (P = 0.028 at the concentration of 1, 10 and 100 nM, 
supplementary Fig. 1a), we tested the effect of EP3 siRNA 
on the proliferation of sulprostone-induced cervical cancer 
cells. As shown in Fig. 2e, co-incubation of EP3 siRNA 
and 100 nM sulprostone reduced the proliferation rate by 
13.9% in HeLa cells (P = 0.043) and by 37.7% in SiHa cells 
(P = 0.028) compared with the non-targeting siRNA with 
100 nM sulprostone after 48 h’ incubation. By contrast, the 
proliferation rate of C-33A cells was neither significantly 
altered by EP3 siRNA (P = 0.33, Fig. 2dD), nor by the com-
bination of 100 nM sulprostone and EP3 siRNA (P = 0.075, 
Fig. 2e).
The inhibitory effect was exhibited when incubating 
100 nM of  PGE2 and L-798,106 (a specific EP3 antagonist) 
with SiHa and C-33A cells, although the effect was not as 
obvious as the effect of EP3 siRNA. The combination of 
 PGE2 and L-798,106 suppressed the proliferation rate by 
14.0% in SiHa cells (P = 0.028, Fig. 2f) and by 10.0% in 
C-33A cells (P = 0.046, Fig. 2f) compared to the vehicle 
(0.05% DMSO) after incubating for 48 h, respectively.
To identify whether EP3 participates the migration of 
cervical cancer cells, we performed wound healing assay. 
Our pre-test showed that 100 nM sulprostone promoted the 
migration rate of HeLa cells by 13.6% for 24 h (P = 0.015, 
supplementary Fig.  1b, c). In comparison, EP3 knock-
down inhibited the migration rate by 20.0% in HeLa cells 
(P = 0.016, Fig. 2g, h) and by 44.2% in SiHa cells (P = 0.006, 
Fig. 2i, j) compared with the negative control. To wrap it up, 
downregulation of EP3 inhibited the proliferation and migra-
tion of HeLa and SiHa cells, while had no effect on C-33A 
cells. The impacts of EP3 knockdown on the proliferation, 
Fig. 2  EP3 knockdown inhibits the proliferation and migration of cer-
vical cancer cells. a The expression of EP3 is higher in HeLa, SiHa 
and C-33A than CaSki cells in the protein level by western blots. 
b The expression of EP3 is higher in HeLa, SiHa and C-33A than 
CaSki cells in the mRNA level detected by primer I with RT-PCR. 
c The downregulated expression of EP3 mRNA is shown in HeLa, 
SiHa and C-33A detected by RT-PCR (*P < 0.05). d BrdU assay sug-
gests the proliferation rate of HeLa and SiHa is decreased by EP3 
knockdown compared to the negative control after 48 h. e The prolif-
eration rate of HeLa and SiHa is inhibited followed by stimulation of 
100 nM sulprostone and EP3 siRNA compared to the negative control 
after 48 h (*P < 0.05). f The proliferation rate of SiHa and C-33A is 
decreased by 100 nM of  PGE2 and L-798,106 compared to the vehi-
cle control after 48 h (0.5% (v/v) DMSO, *P < 0.05). g Representa-
tive photographs show the migration of HeLa cells into the wounded 
area treated with the EP3 siRNA and the negative control after 24 h. 
h We observed that the relative migration rate of HeLa cells is sup-
pressed in the EP3 siRNA group compared to the negative control 
(*P < 0.05). i Representative pictures represent the migration of SiHa 
cells into the wounded area followed by incubating EP3 siRNA and 
the non-targeting control for 24  h. j The relative migration rate of 
SiHa cells is inhibited in the EP3 siRNA group compared to the non-
targeting control (*P < 0.05). Bar graphs represent mean ± SD (n = 6). 
*P < 0.05 is considered as significantly different after comparison 
between the EP3 siRNA and the negative control (N.C)
◂
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migration and expression of PAI-1/uPAR in HeLa, Siha and 
C-33A cells were summarized in Table 1.
EP3 is correlated with PAI‑1 and uPAR in cervical 
cancer tissues
Migration and invasion are responsible for the majority of 
patients death from solid tumors in advanced stages (Paul et al. 
2017), and both of PAI-1 and uPA are involved in the migra-
tion of cervical carcinoma (Fujishiro et al. 1994; Hazelbag 
et al. 2004; Horn et al. 2002; Sugimura et al. 1992). TIMER 
database was applied to identify the correlation between EP3 
and PAI-1 or uPAR. The result showed that EP3 was positively 
correlated with PAI-1 (r = 0.148, P = 9.37 × 10–3, Fig. 3a) and 
negatively correlated with uPAR (r = − 0.174, P = 2.31 × 10–3, 
Fig.  3d). With the GEPIA and UALCAN databases we 
observed that the OS of the low PAI-1 expression group was 
higher than that of the high PAI-1 expression group in the long 
run (P = 0.0093 in GEPIA, Fig. 3b; P = 0.009 in UALCAN, 
Fig. 3c). The OS was not significantly different in the low and 
high uPAR expression groups in GEPIA database (P = 0.055, 
Fig. 3e), whereas the OS of the low uPAR expression group 
was increased than that of the high uPAR expression group in 
UALCAN (P = 0.041, Fig. 3f). Therefore, we examined the 
expression of PAI-1 and uPAR in HeLa and SiHa cells after 
knocking down EP3 and then testified uPAR expression in our 
250 cervical cancer specimens because of the diverse results 
of two databases.
Knockdown of EP3 increases the expression of PAI‑1 
and uPAR
Knockdown of EP3 promoted the production of PAI-1 in the 
supernatants of both HeLa and SiHa cells. Downregulation 
of EP3 enhanced the production of PAI-1 by 38.7% in the 
supernatants of HeLa cells compared to the negative control 
(0.55 ± 0.09 vs 0.40 ± 0.12 ng/ml, P = 0.003, Fig. 4b). The 
same trend was observed in SiHa cells, downregulation of 
EP3 increased the production of PAI-1 in the supernatants 
by 66.1% compared to the negative control (0.67 ± 0.07 vs 
Fig. 3  EP3 is correlated with PAI-1 and uPAR in cervical cancer. a, 
d TIMER database was applied to identify the correlation between 
EP3 and PAI-1 or uPAR, which is based on the CESC (cervical squa-
mous cell carcinoma and endocervical adenocarcinoma) in the Can-
cer Genome Atlas (TCGA) dataset (https ://www.cance r.gov). b, c 
PAI-1 is associated with poor overall survival (OS) of cervical cancer 
patients both in GEPIA database (https ://gepia .cance r-pku.cn/) and 
UALCAN database (https ://ualca n.path.uab.edu/index .html). e, f The 
association of uPAR with poor prognosis of cervical cancer patients 
is significant in UALCAN database but not in GEPIA database
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0.41 ± 0.05 ng/ml, P = 0.003, Fig. 4b). Both phosphorylated 
extracellular signal-regulated kinases 1/2 (p-ERK1/2) and 
p53 are the upstream regulators of PAI-1 gene transcription 
(Samarakoon et al. 2013; Wilkins-Port et al. 2007), hence we 
also analyzed the expression of p-ERK1/2 and p53 by west-
ern blots. The molecular weights of p-ERK1/2 are 44 and 
42 kDa. In SiHa cells, EP3 blockade increased the expres-
sion of p-ERK1/2 by 25.5% (P = 0.028, Fig. 4a, c) while 
did not change the expression of total ERK 1/2 (P = 0.753, 
Fig. 4a, d) compared to the negative control group after incu-
bating EP3 siRNA for 48 h. Silencing EP3 decreased the 
expression of p53 by 7.4% in SiHa cells (P = 0.011, Fig. 4a, 
d). Additionally, the expression of uPAR was also analyzed 
by western blotting and the molecular weight of uPAR is 
between 35–65 kDa. EP3 knockdown improved the expres-
sion of uPAR by 28.6% in SiHa cells (P = 0.027, Fig. 4a, e). 
No alteration of p-ERK1/2, ERK1/2 and p53 was observed 
in HeLa cells while the expression of uPAR was not able to 
be detected in HeLa cells (Fig. 4a).
Expression of uPAR in cervical cancer tissues
Finally, we analyzed uPAR expression in the same group 
of 250 cervical cancer patients as we previously conducted 
(Heidegger et al. 2017) and examined the correlation of 
uPAR expression with clinical-pathological parameters 
and several cervical cancer biomarkers. uPAR staining was 
observed in the cytoplasm of 93.6% (234/250) of cervical 
cancer tissue samples, and the median IRS for cytoplasmic 
uPAR expression was 2.05. Although EP3 was negatively 
correlated with uPAR in the TIMER database, there was no 
significant correlation between uPAR and EP3 expression 
Fig. 4  Expression of plasminogen activator inhibitor type 1 (PAI-1) 
and urokinase-type plasminogen activator receptor (uPAR) is influ-
enced by silencing EP3 gene. a Western blotting analysis shows the 
expression of phosphorylated extracellular signal-regulated kinases 
(p-ERK1/2), extracellular signal-regulated kinases (ERK1/2), p53 
and uPAR in HeLa and SiHa cells following treatment with EP3 
siRNA and the negative control (N.C) for 48 h. β-actin was used as 
a loading control and all the data was normalized to the β-actin band 
signals. b PAI-1 levels in the supernatants of HeLa and SiHa cells 
are enhanced after silencing EP3 compared with the negative con-
trol for 48 h by ELISA (*P < 0.05, n = 6). c The histogram illustrates 
the expression of p-ERK1/2 is increased after silencing EP3 gene for 
48 h in SiHa cells (*P < 0.05). d The histogram presents the expres-
sion of ERK1/2 is not altered by EP3 siRNA in HeLa and SiHa cells 
(P > 0.05). e The histogram illustrates the expression of p53 is inhib-
ited after downregulation of EP3 compared with the negative control 
for 48 h in SiHa cells (*P < 0.05). f The histogram shows the expres-
sion of uPAR is stimulated after EP3 knockdown compared with 
the negative control for 48  h in SiHa cells (*P < 0.05). Statistically 
significant differences (P < 0.05) between EP3 siRNA group and the 
negative control group are marked with an *. All western blots data 
are shown as mean ± SD (n = 3). Full-length blots are shown in Sup-
plementary Fig. 2
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in our cervical cancer specimens (P = 0.822, Table 2). How-
ever, a significant negative correlation was shown between 
uPAR expression and FIGO status (spearman’s rank correla-
tion Rho = − 0.165; P = 0.012), suggesting the weaker uPAR 
staining was correlated with a higher FIGO stage (Table 1). 
Additionally, decreased uPAR staining was observed in 
cervical cancer cases with higher FIGO stages (P = 0.046, 
Fig. 5a). A total of 44.8% (112/250) of cervical cancer 
patients with FIGO stages I/II had a median IRS of 2.17 
compared to 17.6% of patients (44/250) with FIGO stages 
III/IV and with a median IRS of 1.52 (Fig. 5a).
The cut off value of IRS 2 was obtained from receiver 
operator curve (ROC) analysis. We observed that uPAR pos-
itivity (IRS ≥ 2) in general was not related to OS in our non-
stratified patient samples (P = 0.48). However, when patients 
had been stratified according to FIGO stage, the high expres-
sion of uPAR was correlated with poor prognosis in OS of 
cervical cancer patients with FIGO stages III/IV as shown 
in the Kaplan–Meier curve (P = 0.047, Fig. 5b). Among all 
the 44 advanced cervical cancer patients (FIGO III/IV), 34 
cases with squamous cell carcinoma had a median IRS of 
1.12 and 10 cases with adenocarcinoma had a median IRS 
of 2.9, which showed no significant difference between these 
two histological subtypes (P = 0.09). The subsequent sur-
vival analysis of the two main histological subtypes sug-
gested a significant negative correlation of uPAR with OS 
in squamous cell carcinoma (P = 0.006, Fig. 5c), but not in 
cervix adenocarcinoma (P = 0.536, Fig. 5d). The representa-
tive cytoplasmic expression of uPAR in the squamous cell 
carcinoma and adenocarcinoma were shown in Fig. 5, and 
metastatic colon carcinoma tissues were applied as nega-
tive and positive controls (Supplementary Fig. 3A, B). It 
indicated that immunopositivity of uPAR was predictive for 
OS in cervical cancer patients of advanced stage (FIGO III/
IV), especially among cases with squamous cell carcinoma. 
In advanced cervical cancer patients (FIGO III/IV), uPAR 
was nearly a promising prognosticator for advanced cervical 
cancer patient OS (P = 0.067, Table 3) tested by multivariate 
Cox regression analysis.
Moreover, we detected a significant positive correlation of 
uPAR with histone H3 tri methyl K4 (H3K4me3, P = 0.041, 
Rho = 0.134) and a significant negative correlation with pN 
(P = 0.017, Rho = − 0.156), p16 (P = 0.05, Rho = − 0.13) 
and galectin-3 (P = 0.002, Rho = − 0.202) in 250 cervical 
cancer tissues (Table 1). The percentage of uPAR positive 
staining cells was negatively associated with the intensity 
of wild-type p53 staining in the cytoplasm (P = 0.011, 
Rho = − 0.184, data not shown), although no correlation 
between uPAR and wild-type nuclear p53 (P = 0.118) or 
between uPAR and mutant p53 in the nucleus (P = 0.082).
Discussion
Our latest study demonstrated that high expression of 
EP3 (IRS ≥ 2) is associated with poor prognosis in the OS 
rate of 250 cervical cancer patients in both squamous cell 
carcinoma and adenocarcinoma (Heidegger et al. 2017). 
EP3 can increase the migration of HCA-7 human colon 
cancer cells through the activation of phosphatidylinosi-
tol 3-kinase (PI3K) and the phosphorylation of ERK1/2 
Table 2  Correlation analysis of uPAR and variables
Bold numbers represent significant correlations
pT tumor stage, pN lymph node stage, pM distant metastasis stage, 
FIGO the International Federation of Gynecology and Obstetrics, 
EP3 prostaglandin  E2 receptor 3, MDM2 MDM2 proto-oncogene, 
GPER G-protein-coupled estrogen receptor, H3K9ac histone H3 
acetyl K9, H3K4me3 histone H3 tri methyl K4
Variables P value Correlation 
coefficient
Histology 0.247 0.076
pT 0.117 − 0.103
pN 0.017* − 0.156
pM 0.308 − 0.067
Grading 0.397 0.056
FIGO 0.012* − 0.165
EP3 0.822 − 0.015
E6 0.836 0.014
p16 0.05* − 0.130
Wild-type p53 0.118 − 0.103
Mutant p53 0.082 − 0.114
MDM2 0.938 − 0.005
galectin-3 0.002* − 0.202
GPER 0.52 − 0.042
H3K9ac 0.121 − 0.102
H3K4me3 0.041* 0.134
Fig. 5  The expression of urokinase-type plasminogen activator 
receptor (uPAR) in cervical cancer patients. a Boxplot shows uPAR 
staining in cervical cancer patients with FIGO I and II is higher than 
in cases with FIGO III and IV (P = 0.046). b High uPAR expres-
sion (IRS ≥ 2) is associated with a shorter overall survival (OS) 
in advanced cervical cancer patients (FIGO III/IV) (P = 0.047). c 
High uPAR expression (IRS ≥ 2) is associated with a shorter OS of 
advanced patients in cervical squamous cell carcinoma (P = 0.006). d 
uPAR survival function of cervical adenocarcinoma in patients with 
FIGO stages III/IV (P = 0.536). e Representative photomicrographs 
of uPAR staining in cervical squamous cell carcinoma (FIGO IIIB) 
with the IRS score of 3. f Representative photomicrographs of uPAR 
staining in cervical squamous cell carcinoma (FIGO IIIB) with the 
IRS score of 0. g Representative photos of uPAR immunohistochemi-
cal staining in adenocarcinoma (FIGO IIIA) with the IRS score of 
4. h Representative photos of uPAR immunohistochemical staining 
in adenocarcinoma (FIGO IVB) with the IRS score of 0. The scale 
bars in the outer pictures equal 200 µm (× 10 magnification) and the 
scale bars in the inserts equal 100 µm (× 50 magnification). FIGO the 
International Federation of Gynecology and Obstetrics
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signaling pathway (Fujino et al. 2011). In accordance to 
those findings, we found that sulprostone (an EP1/EP3 
agonist) induced the proliferation and migration of HeLa 
cells, while silencing EP3 reduced the proliferation and 
migration of HeLa and SiHa cells. In contrast to colon 
cancer cells, EP3 silenced SiHa cells showed elevated 
expression of phosphorylated-ERK1/2. The latter was in 
accordance with a study demonstrating that activation of 
EP3 signaling reduced ERK phosphorylation in rat cer-
ebellar astrocytes (Paniagua-Herranz et al. 2017).
With bioinformatics, signaling pathways of ECM recep-
tor interaction, adheren junction and cell adhesion mole-
cules were enriched when EP3 was upregulated in cancer 
microenvironment. Additionally, we observed that EP3 was 
positively associated with PAI-1 in cervical malignancy, 
and PAI-1 was correlated with the OS of cervical cancer 
patients in both UALCAN and GEPIA databases. Studies 
also proved that PAI-1 is an independent prognosticator in 
cervical cancer (Hazelbag et al. 2004; Horn et al. 2002). 
Therefore, we deduced that EP3 and PAI-1 are involved in 
the tumor migration of cervical tumor.  PGE2 can increase 
mRNA and protein levels of PAI-1 by binding with EP1/
EP3 receptor in rat ventricular fibroblasts, contributing to 
elevated fibrin deposition in aortic stenosis (Kassem et al. 
2014). However, Sato et al. suggested that TM5275 (a small 
molecular inhibitor of PAI-1) can increase the collagenase 
activity of SiHa and CaSki cells (Sato et al. 2016), imply-
ing that lower expression of PAI-1 benefits the ECM degra-
tion and cervical cancer migration. The latter study was in 
accordance with our study that silencing EP3 increased the 
production of PAI-1 and decreased the migration in HeLa 
and SiHa cells. Conflicting effects of PAI-1 on migration 
might due to the different distances of cervical cancer cells 
from basal membrane (Sato et al. 2016).
In comparison, EP3 expression was negatively associ-
ated with uPAR expression in CESC. The correlation of 
uPAR with OS of cervical cancer patients was significant in 
UALCAN but not GEPIA. Sasaki et al. testified that over-
expression of uPAR mRNA is related to a shorter DFS of 
cervical cancer patients, however, the immunohistochemi-
cal staining of uPAR was not very intense (Sasaki et al. 
2014). In the present study, we detected only those patients 
with an uPAR expression (IRS ≥ 2) showed a poor OS in 
the subgroup of advanced stage (FIGO III/IV) cases. The 
negative correlation of uPAR with OS of patients was sig-
nificant in squamous cell carcinoma but not in cervix adeno-
carcinoma, which could be due to the smaller number of 
patients with adenocarcinoma (n = 10) or different patho-
logical molecular mechanisms in squamous cell carcinoma 
and adenocarcinoma. This result agreed with multivariate 
Cox regression analysis, indicating that with a large scale of 
specimens, uPAR could be a promising prognosticator for 
OS of advanced cervical cancer patients.
Magnussen et al. (2017) proved that high production of 
PAI-1 can reduce uPAR cleavage to inhibit the migration 
of oral squamous cell carcinoma (OSCC) and the cleaved 
soluble uPAR is responsible for promoting the migration of 
OSCC cells (Magnussen et al. 2017). Jing et al. also sug-
gested that the soluble uPAR in serum is a prognosis marker 
as well as a tumor biomarker for clinical diagnosis and 
treatment of cervical cancer (Jing et al. 2012). The in vitro 
studies showed knockdown of EP3 increased expression of 
uPAR and PAI-1 in SiHa cells. Therefore, we deduced that 
the upregulated secretion of PAI-1 decreased uPAR cleavage 
in EP3 knockdown SiHa cells causing less soluble uPAR in 
the ECM and leaving more uPAR on the membrane, and 
these might contribute to decreased migration of SiHa cells 
(Fig. 6).
Interestingly, TGF-β signaling pathway was found to be 
significantly enriched when EP3 gene was upregulated in 
the CESC. Many studies illustrate the gene transcription 
of PAI-1 is regulated by TGF-β1 through various signal-
ling pathways, one of which is through phosphorylation of 
ERK1/2 (Wilkins-Port et al. 2007). The cross-talks among 
reactive oxygen species (ROS), tumor suppressor p53, and 
upstream stimulatory factor proteins 1/2 (USF1/2) are nec-
essary for TGF-β1 inducing PAI-1 transcription (Freytag 
et al. 2009; Samarakoon et al. 2013). This gave a hint that 
EP3 signaling possibly modulates PAI-1 gene transcription 
through similar signalling pathways as TGF-β1. We proved 
that EP3 blockade increased the expression of PAI-1 and 
p-ERK1/2 and decreased the expression of p53 in SiHa 
cells. Furthermore, decreased expression of wild-type p53 
in the cytoplasm of cervical cancer tissues was correlated 
to increased expression of uPAR. This in vivo finding was 
in good agreement with the previous report that HPV E6 
oncoproteins induce rapid degradation of tumor suppressor 
protein p53 to prevent the host cell from inducing apoptosis 
(DeFilippis et al. 2003). It implied that p53 might translocate 
into the nucleus from the cytoplasm to induce PAI-1 tran-
scription. However, this deduction concerning p53 transloca-
tion should be explored in further studies.
Our group previously found other biomarkers of cervical 
cancer, such as p16 (Stiasny et al. 2017), MDM2 (Stiasny et al. 
2017), galectin-3 (Stiasny et al. 2017), H3K9ac (Beyer et al. 
2017) and H3K4me3 (Beyer et al. 2017). Therefore, we also 
analyzed the correlation of uPAR with these biomarkers in the 
same cervical cancer patients. First, we found that a negative 
correlation of uPAR with both galectin-3 and p16 in cervical 
cancer patients. Stiasny et al. showed that galectin-3 expres-
sion was correlated with a shorter survival time in cervical 
cancer patients expressing no or very low p16 (Stiasny et al. 
2017). In hepatocellular carcinoma cells, galectin-3 silencing 
attenuated uPAR expression and inhibited the proliferation, 
migration and invasion (Zheng et al. 2014). This study was 
also in line with our detections that low expression of uPAR 
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was correlated with longer survival time in cervical cancer 
patients with advanced stage. Additionally, the positive cor-
relation of H3K4me3 and uPAR expression in our study was 
in accordance with the finding that H3K4me3 is related to poor 
prognosis in cervical cancer patients and is an independent 
marker of relapse-free survival (Beyer et al. 2017). Although 
EP3 seems not to correlate with the expression of the direct 
HPV marker protein E6 (P = 0.192, data not shown) or with 
the indirect protein p16 (P = 0.267, data not shown), there is a 
link between uPAR and p16 (P = 0.05, Table 2). This link was 
already found in migrating keratinocytes. Migration seems to 
Table 3  Cox regression of 
clinical-pathological variables 
regarding overall survival in 
cervical cancer patients with 
FIGO III/IV (n = 44)
IRS Immunoreactive score, pN lymph node stage, pT tumor stage, pM distant metastasis stage, FIGO the 
International Federation of Gynecology and Obstetrics




uPAR IRS 0.067 8.332 0.863 80.425
Histology 0.222 5.182 0.370 72.505
pT 0.231 2.056 0.632 6.687
pN 0.987 4,553,661.9 0.000 –
pM 0.314 0.193 0.008 4.734
Grading 0.255 3.664 0.391 34.350
FIGO 0.962 0.974 0.331 2.865
Age 0.588 1.031 0.922 1.153
Fig. 6  Hypothetic schema of EP3 signaling in the migration of 
human cervical cancer cells. Inhibiting EP3 signaling contributes to 
phosphorylation of extracellular signal-regulated kinases (p-ERK1/2) 
and translocation of p53 from the cytoplasm to the nucleus, result-
ing in an increased transcription of PAI-1. High expression of PAI-1 
reduces uPAR cleavage (Magnussen et  al. 2017), thus leading to 
decreased migration of cervical cancer cells. The EP3 signaling path-
way is similar to the one that transforming growth factor-β1 (TGF-β1) 
induces PAI-1 gene expression via the rapid generation of reactive 
oxygen species (ROS), phosphorylation of ERK1/2 and the mobili-
zation of p53 signaling (Samarakoon et al. 2013; Wilkins-Port et al. 
2007). In addition, cytoplasmic p53 is decreased in the cervical can-
cer cells with high expression of uPAR, which is correlated with poor 
prognosis in overall survival rates of cervical cancer patients with 
advanced FIGO stages (III/IV). Therefore, we believed that EP3 sign-
aling regulates the migration of cervical cancer cells through plasmi-
nogen activator inhibitor type 1 (PAI-1) and urokinase-type plasmino-
gen activator receptor (uPAR)
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be stimulated by a combined upregulation of both p16INK4a 
and an activated uPAR signaling (Darbro et al. 2005).
The upregulated expression of p-ERK1/2 was observed in 
SiHa cells while the expression of ERK1/2 was too low to 
draw any conclusion in HeLa cells. HeLa cells are catego-
rized as adenocarcinoma and SiHa cells are squamous cell 
carcinoma according to the ATCC. The different pathological 
molecular mechanisms in cancer development should be inves-
tigated between squamous cell carcinoma and adenocarcinoma 
in the future. Another limitation of this investigation is that it is 
a retrospective study, which analyzed the data of patients who 
had undergone surgeries in one single hospital from 1993 to 
2002. A multi-centre prospective study should be carried out 
for further research, as well as the xenograft mice experiments.
Conclusions
Taken all results together, EP3 might facilitate the migra-
tion of cervical cancer cells through modulating the pro-
duction of PAI-1 and uPAR in advantaged stages of cervi-
cal malignancy. The high production of PAI-1 might due 
to the phosphorylation of ERK1/2 and translocation of 
p53 from the cytoplasm into the nucleus after sliencing 
EP3. The high expression of PAI-1 inhibits the cleavage 
of uPAR (Magnussen et al. 2017), contributing to inhib-
ited migration of cervical cancer cells (Fig. 6). EP3 and 
uPAR might represent novel therapeutic targets for cervi-
cal cancer and specific antagonists or inhibitors of EP3 
and uPAR could be promising therapeutic treatments for 
cervical cancer.
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